Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Lymphomas Trial Data From the ASCO 2022 and EHA 2022 Annual Meetings

July 13th 2022

Shared insight from expert oncologists on key clinical trial data in lymphomas from the ASCO 2022 and EHA 2022 Annual Meetings.

Acute Lymphocytic Leukemia Trial Data From the ASCO 2022 and EHA 2022 Annual Meetings

July 13th 2022

Expert oncologist perspectives on key clinical trial data in acute lymphocytic leukemia from the ASCO 2022 and EHA 2022 Annual Meetings.

Ibrutinib/Obinutuzumab Combo Elicits Durable Responses in Relapsed/Refractory CLL

July 13th 2022

Findings from a phase 1b trial showed that the addition of obinutuzumab to ibrutinib produced a complete response rate that compared favorably with what has historically been observed with ibrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.

Camidanlumab Tesirine Elicits Encouraging Responses in Relapsed/Refractory Classical Hodgkin Lymphoma

July 12th 2022

Camidanlumab tesirine induced an overall response rate of 70.1% in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma who previously received brentuximab vedotin and a PD-1 blockade with or without stem cell transplant.

Survival is Significantly Poorer for Young Black Patients With AML Compared With White Counterparts

July 11th 2022

Despite receiving similar treatment, Black patients between the ages of 18 and 29 years with acute myeloid leukemia were twice as likely to die within 5 years compared with Whites.

Women in Oncology: Career Obstacles Turned Into Opportunities

July 11th 2022

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, share the challenges they chose to mold into career goals, including developing a new technology to study cell cytokinetics, identifying gene phenotypes, and recognizing that leukemia diseases stem from the same root issues in DNA.

Individualized Care Drives Treatment Focus in AML, DLBCL, and CLL

July 11th 2022

Ehab Atallah, MD, explains how patient characteristics influence current treatment strategies in acute myeloid leukemia, how frontline pirtobrutinib may move toward use in chronic lymphocytic leukemia, and the growing evidence favoring CAR T-cell therapy as an effective treatment option in CLL.

Graft Versus Host Disease: Optimizing Prophylaxis Techniques

July 11th 2022

Shared insight on standard-of-care prophylactic methods employed in the management of patients with graft versus host disease.

Understanding Pathophysiology and Risk of Graft Versus Host Disease

July 11th 2022

Expert panelists spearhead a discussion on the pathophysiology driving both acute and chronic graft versus host disease.

Anbalcabtagene Autoleucel Elicits Meaningful Responses in Relapsed/Refractory LBCL

July 8th 2022

The CAR T-cell therapy anbalcabtagene autoleucel generated strong overall response rates in patients with relapsed/refractory large B-cell lymphoma.

Women in Oncology: How Leukemia Treatment has Changed and Stayed Stagnant Over the Years

July 8th 2022

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, highlight the decades-long evolution of the leukemia field and express challenges such as defining the causes of leukemia and developing therapies to treat the disease and mitigate adverse effects like bone pain.

Belantamab Mafodotin Plus Lenalidomide/Dexamethasone Shows Efficacy, Safety in Newly Diagnosed Myeloma

July 8th 2022

The addition of belantamab mafodotin-blmf to lenalidomide and dexamethasone generated responses with acceptable safety in patients with newly diagnosed multiple myeloma who were ineligible to undergo autologous stem cell transplant.

Hematologic Improvements With Ivosidenib + Azacitidine Compared to Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia

July 7th 2022

Dr. Pau Montesinos reviews the efficacy of ivosidenib and azacitidine in reducing transfusions and improving blood counts in patients with newly diagnosed acute myeloid leukemia.

Expanding Opportunities for Real-World Evidence in Oncology

July 7th 2022

Real-world evidence is finding an expanded role in oncology, prompting experts to rethink how data are gathered on the day-to-day usefulness of drugs for regulatory decisions.

Clinical Scenario 2: A 66-Year-Old Woman with Locally Advanced Basal Cell Carcinoma

July 7th 2022

Jennifer Atlas, MD, presents the case of a 66-year-old woman with locally advanced basal cell carcinoma not responding to frontline treatment.

Tafasitamab plus Lenalidomide as a Treatment in Patients With R/R DLBCL

July 7th 2022

Oncologists discuss the efficacy and safety of a tafasitamab plus lenalidomide for relapsed/refractory DLBCL and share personal experiences relevant to its use.

Defining Chronic or Persistent Immune Thrombocytopenia

July 7th 2022

Expert perspectives on how to identify chronic or persistent disease in patients diagnosed with immune thrombocytopenia.

Selecting Among Available Treatment Options for Patients With Relapsed/Refractory DLBCL

July 7th 2022

Caron Jacobson, MD, and Matthew Lunning, DO, FACP, assess the available treatment options for patients with R/R DLBCL.

The Significance of Patient Age in Treatment and Management of ITP

July 7th 2022

A commentary on the significance of the patient’s age in treating and managing ITP.

FDA Grants Priority Review to Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma

July 6th 2022

The FDA has accepted a biologics license application and granted a priority review designation to mosunetuzumab, a potential first-in-class CD20 and CD3 T-cell engaging bispecific antibody, for the treatment of patients with relapsed/refractory follicular lymphoma following at least 2 prior systemic therapies.